Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions

A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a novel PI3K inhibitor, XL765, administered orally to patients (pts) with advanced solid tumors

(2017) K. P. Papadopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY

Cilengitide in newly diagnosed glioblastoma with MGMT promoter methylation: Protocol of a multicenter, randomized, open-label, controlled phase III trial (CENTRIC).

(2017) R. Stupp et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

(2017) Sith Sathornsumetee et al.   NEURO-ONCOLOGY

The Plasticity of Oncogene Addiction: Implications for Targeted Therapies Directed to Receptor Tyrosine Kinases

(2015) Vinochani Pillay et al.   NEOPLASIA

Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway

(2012) Ke Sai et al.   JOURNAL OF NEURO-ONCOLOGY

Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion

(2011) Walter Stummer et al.   ACTA NEUROCHIRURGICA

AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme

(2011) O. L. Chinot et al.   ADVANCES IN THERAPY

Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors

(2011) Arkaitz Carracedo et al.   CELL CYCLE

Antiangiogenic therapy for patients with glioblastoma: current challenges in imaging and future directions

(2011) Manmeet S Ahluwalia et al.   Expert Review of Anticancer Therapy

Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study

(2011) John F. de Groot et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma

(2011) David A. Reardon et al.   JOURNAL OF NEURO-ONCOLOGY

A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy

(2011) J. J. Raizer et al.   NEURO-ONCOLOGY

Pathway inhibition: emerging molecular targets for treating glioblastoma

(2011) W. Wick et al.   NEURO-ONCOLOGY

Clinical trial end points for high-grade glioma: the evolving landscape

(2011) D. A. Reardon et al.   NEURO-ONCOLOGY

A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma

(2011) P. Y. Wen et al.   NEURO-ONCOLOGY

A Novel Extracellular Hsp90 Mediated Co-Receptor Function for LRP1 Regulates EphA2 Dependent Glioblastoma Cell Invasion

(2011) Udhayakumar Gopal et al.   PLoS One

Perifosine and CCI 779 Co-Operate to Induce Cell Death and Decrease Proliferation in PTEN-Intact and PTEN-Deficient PDGF-Driven Murine Glioblastoma

(2011) Kenneth L. Pitter et al.   PLoS One

Notch signaling in glioblastoma: a developmental drug target?

(2010) Maria Maddalena Lino et al.   BMC Medicine

Targeting SRC in glioblastoma tumors and brain metastases: Rationale and preclinical studies

(2010) Manmeet S. Ahluwalia et al.   CANCER LETTERS

A Dual PI3K/mTOR Inhibitor, PI-103, Cooperates with Stem Cell-Delivered TRAIL in Experimental Glioma Models

(2010) T. Bagci-Onder et al.   CANCER RESEARCH

 -Secretase Inhibitors Enhance Temozolomide Treatment of Human Gliomas by Inhibiting Neurosphere Repopulation and Xenograft Recurrence

(2010) C. A. Gilbert et al.   CANCER RESEARCH

Integrin Alpha 6 Regulates Glioblastoma Stem Cells

(2010) Justin D. Lathia et al.   Cell Stem Cell

Nimotuzumab for pediatric diffuse intrinsic pontine gliomas

(2010) Maura Massimino et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Therapeutic targeting of EGFR in malignant gliomas

(2010) Fei Ye et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma

(2010) Roger Stupp et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma

(2010) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma

(2010) Tracy T. Batchelor et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma

(2010) David A. Reardon et al.   JOURNAL OF NEURO-ONCOLOGY

Phase II study of sunitinib malate in patients with recurrent high-grade glioma

(2010) B. Neyns et al.   JOURNAL OF NEURO-ONCOLOGY

Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma

(2010) Surasak Phuphanich et al.   JOURNAL OF NEURO-ONCOLOGY

ZD6474, a Multitargeted Inhibitor for Receptor Tyrosine Kinases, Suppresses Growth of Gliomas Expressing an Epidermal Growth Factor Receptor Mutant, EGFRvIII, in the Brain

(2010) Jia-Jean Yiin et al.   MOLECULAR CANCER THERAPEUTICS

Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: A phase I study

(2010) N. Butowski et al.   NEURO-ONCOLOGY

Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)

(2010) F. M. Iwamoto et al.   NEURO-ONCOLOGY

Progress on Antiangiogenic Therapy for Patients with Malignant Glioma

(2010) Manmeet S. Ahluwalia et al.   Journal of Oncology

Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma

(2009) B. Neyns et al.   ANNALS OF ONCOLOGY

Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents

(2009) W. Yang et al.   APPLIED RADIATION AND ISOTOPES

Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor

(2009) Jerry Y. Hsu et al.   BIODRUGS

Convection-enhanced delivery of nanocarriers for the treatment of brain tumors

(2009) Emilie Allard et al.   BIOMATERIALS

Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma

(2009) D A Reardon et al.   BRITISH JOURNAL OF CANCER

Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma

(2009) David A. Reardon et al.   CANCER

Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway

(2009) Kim-Son H. Nguyen et al.   Clinical Lung Cancer

Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity

(2009) William Kells Boland et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Edema Control by Cediranib, a Vascular Endothelial Growth Factor Receptor–Targeted Kinase Inhibitor, Prolongs Survival Despite Persistent Brain Tumor Growth in Mice

(2009) Walid S. Kamoun et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

(2009) Evanthia Galanis et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme

(2009) David M. Peereboom et al.   JOURNAL OF NEURO-ONCOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy

(2009) Y. Li et al.   MOLECULAR CANCER THERAPEUTICS

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Integrins

(2008) Rita Silva et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

HIF1α Induces the Recruitment of Bone Marrow-Derived Vascular Modulatory Cells to Regulate Tumor Angiogenesis and Invasion

(2008) Rose Du et al.   CANCER CELL

Oncogene Addiction

(2008) I. B. Weinstein et al.   CANCER RESEARCH

Targeting Cancer Stem Cells through L1CAM Suppresses Glioma Growth

(2008) S. Bao et al.   CANCER RESEARCH

Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme

(2008) David A. Reardon et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Imatinib in Patients With Recurrent Gliomas of Various Histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group Study

(2008) Eric Raymond et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety

(2008) Tyler Y. Kang et al.   JOURNAL OF NEURO-ONCOLOGY

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE

Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas

(2008) Kathleen R. Lamborn et al.   NEURO-ONCOLOGY

VEGF Trap induces antiglioma effect at different stages of disease

(2008) Candelaria Gomez-Manzano et al.   NEURO-ONCOLOGY

Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells

(2008) Claire Marie-Elisabeth Sauvageot et al.   NEURO-ONCOLOGY

Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence

(2008) A. D. Norden et al.   NEUROLOGY

Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma

(2008) Tim F Cloughesy et al.   PLOS MEDICINE